Alzheimers Research & Therapy

Article	Citations
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	440
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment	158
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering	158
Cognitive impact of COVID-19: looking beyond the short term	146
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease	137
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study	123
Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review	115
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia	111
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review	110
Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment	106
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease	101
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice	99
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231	97
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach	81
The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study	79
Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome	77
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals	75
Portals to frailty? Data-driven analyses detect early frailty profiles	72
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias	69
Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort	66
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial	66
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice	65
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study	65
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease	65
The Alzheimer’s disease drug development landscape	63

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease	62
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis	60
In vivo tau pathology is associated with synaptic loss and altered synaptic function	59
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration	58
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review	58
The accuracy and robustness of plasma biomarker models for amyloid PET positivity	57
Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J	57
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease	56
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease	56
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis	55
Retinal microvasculature dysfunction is associated with Alzheimer’s disease and mild cognitive impairment	55
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression	53
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease	53
The insulin resistance by triglyceride glucose index and risk for dementia: population-based study	52
Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease	51
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery	50
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6	50
Melatonin levels in the Alzheimer’s disease continuum: a systematic review	49
GPS driving: a digital biomarker for preclinical Alzheimer disease	48
Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease	48
Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review	47
Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration	47
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach	47
Enhancing magnetic resonance imaging-driven Alzheimer’s disease classification performance using generative adversarial learning	46
Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants	45
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease	45
Herpesvirus infections and Alzheimer’s disease: a Mendelian randomization study	44
Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer’s dementia	44
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease	44
Glucose metabolism and AD: evidence for a potential diabetes type 3	43
Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer’s disease	43
Huanglian Jiedu decoction remodels the periphery microenvironment to inhibit Alzheimer’s disease progression based on the “brain-gut” axis through multiple integrated omics	42
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6	42
Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer’s disease created by integrative analysis of multi-omics data	42
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease	41
Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations	41
The efficacy of exergaming in people with major neurocognitive disorder residing in long-term care facilities: a pilot randomized controlled trial	41
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes	41
Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer’s disease with an implantable ultrasound device	40
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease	38
Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study	38
Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer’s disease patients	38
In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases	37
Detection of dementia on voice recordings using deep learning: a Framingham Heart Study	37
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline	37
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative	37
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project	37
MIND diet and the risk of dementia: a population-based study	37
TREM2 Alzheimer’s variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages	36
An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease	36

Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer’s disease using EEG technology	36
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?	35
Apolipoprotein E and sex modulate fatty acid metabolism in a prospective observational study of cognitive decline	35
The dynamics of plasma biomarkers across the Alzheimer’s continuum	35
Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network	34
Trichostatin A ameliorates Alzheimer’s disease-related pathology and cognitive deficits by increasing albumin expression and Aβ clearance in APP/PS1 mice	34
Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study	34
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217	34
Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population	33
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	33
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study	33
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrie	33
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease	32
Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer’s disease	32
Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?	32
Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction	32
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy	32
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial	32
Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum	32
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review	31
Distinct network topology in Alzheimer’s disease and behavioral variant frontotemporal dementia	31
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	31
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6	31
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease	31
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	31
RETRACTED ARTICLE: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis	31
The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer’s disease	31
Deep learning-based speech analysis for Alzheimer’s disease detection: a literature review	30
Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers	30
Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systemati	30
Early detection of amyloid load using 18F-florbetaben PET	29
Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease	29
Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning	29
Perspectives and challenges in patient stratification in Alzheimer’s disease	29
Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model	29
Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer’s disease	29
White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer’s disease	29
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	29
Verbal intelligence is a more robust cross-sectional measure of cognitive reserve than level of education in healthy older adults	29
The effect of music therapy on cognitive functions in patients with Alzheimer’s disease: a systematic review of randomized controlled trials	28
Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning	28
The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone	28
Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis	28
Use of the Clock Drawing Test and the Rey–Osterrieth Complex Figure Test-copy with convolutional neural networks to predict cognitive impairment	27
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6	27
Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study	27
Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice	27
Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation	27
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults	26
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration	26
Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE	26
Race, APOE genotypes, and cognitive decline among middle-aged urban adults	26
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients	25
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease	25
Associations between locus coeruleus integrity and nocturnal awakenings in the context of Alzheimer’s disease plasma biomarkers: a 7T MRI study	24
A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers	24
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease	24
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease	24
Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology	24
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease	23
Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer’s dementia	23
Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study	23
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease	23
Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study	23
Serum neurofilament light chain level as a predictor of cognitive stage transition	23
Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer’s disease	23
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease	23
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease	23
Shared genetic risk loci between Alzheimer’s disease and related dementias, Parkinson’s disease, and amyotrophic lateral sclerosis	23
Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study	22
Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts	22
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort	22
Association between physical activity and conversion from mild cognitive impairment to dementia	22
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	22
High-intensity exercise and cognitive function in cognitively normal older adults: a pilot randomised clinical trial	22
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease	22
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	22
Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial	21
Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results	21
β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer’s disease and predicts cerebral amyloidosis	21

Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX	21
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design	21
Role of liraglutide in Alzheimer’s disease pathology	20
Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease	20
27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial	20
Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an obse	20
Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial	20
COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients	20
Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer’s disease: a Mendelian randomization study	20
Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease	20
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	20
Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy	20
Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease	20
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individ	20
A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease	20
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912	20
Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis	19
Behavioral, neuromorphological, and neurobiochemical effects induced by omega-3 fatty acids following basal forebrain cholinergic depletion in aged mice	19
Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis	19
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients	19
Economic and caregiver impact of Alzheimer’s disease across the disease spectrum: a cohort study	19
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform	19
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort	19
High-intensity physical activity is not associated with better cognition in the elder: evidence from the China Health and Retirement Longitudinal Study	18
Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study	18
A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study	18
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model	18
Self-Administered Gerocognitive Examination: longitudinal cohort testing for the early detection of dementia conversion	18
Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer’s disease dementia	18
A novel age-informed approach for genetic association analysis in Alzheimer’s disease	18
Multi-trait association studies discover pleiotropic loci between Alzheimer’s disease and cardiometabolic traits	17
Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-β deposition in Alzheimer’s disease	17
Differences between memory encoding and retrieval failure in mild cognitive impairment: results from quantitative electroencephalography and magnetic resonance volumetry	17
Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults	17
What’s the cut-point?: a systematic investigation of tau PET thresholding methods	17
Grey matter changes on brain MRI in subjective cognitive decline: a systematic review	17
Recurrent and concurrent patterns of regional BOLD dynamics and functional connectivity dynamics in cognitive decline	17
Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia	17
Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease	17
Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET	17
CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease	17
Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease	17
Anticancer drugs repurposed for Alzheimer’s disease: a systematic review	16
Visuospatial alpha and gamma oscillations scale with the severity of cognitive dysfunction in patients on the Alzheimer’s disease spectrum	16
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease	16
APOE ε4, Alzheimer’s disease neuropathology and sleep disturbance, in individuals with and without dementia	16
Stress, depression, and risk of dementia – a cohort study in the total population between 18 and 65 years old in Region Stockholm	16
Characteristics of very late-onset schizophrenia-like psychosis as prodromal dementia with Lewy bodies: a cross-sectional study	16
Gut–microbiota–microglia–brain interactions in Alzheimer’s disease: knowledge-based, multi-dimensional characterization	16
Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study	16
Additive interaction of mid- to late-life depression and cerebrovascular disease on the risk of dementia: a nationwide population-based cohort study	16
Enriched gardens improve cognition and independence of nursing home residents with dementia: a pilot controlled trial	16
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia study	16
The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia	16
Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6	16
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease	15
The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice	15
Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy	15
N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA rece	15
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease	15
Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study	15
Admixture mapping reveals the association between Native American ancestry at 3q13.11 and reduced risk of Alzheimer’s disease in Caribbean Hispanics	15
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study	15
Serum zinc levels and in vivo beta-amyloid deposition in the human brain	15
Cognitive training and brain stimulation in prodromal Alzheimer’s disease (AD-Stim)—study protocol for a double-blind randomized controlled phase IIb (monocenter) trial	15
Sex-specific associations between lipids and cognitive decline in the middle-aged and elderly: a cohort study of Chinese adults	15
Association of neurofilament light chain with renal function: mechanisms and clinical implications	15
Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans	15
Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease	15
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	15